QDELNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends January 1
QuidelOrtho Corp
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 7, 2026
$12.76−0.15 (-1.16%)
Close on Oct 19, 2026
- Market cap
- $871.51M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$15.37 (−54.64%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
QuidelOrtho Corp saw revenue fall 2.5% to $2.67B over the twelve months to Jun 28, 2026. Free cash flow was -$211.20M, down 1724.6% from a year earlier.
Revenue
$2.67B
-2.5% vs. a year earlier
Operating income
-$824.70M
TTM Q2 2026
Free cash flow
-$211.20M
-1724.6% vs. a year earlier
EPS, diluted
-$15.41
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 28, 2026
Valuation
- Market cap
- $871.51M
- P/E ratio
- –
- Price to sales
- 0.33
- Price to book
- 0.49
- Dividend yield
- –
- Free cash flow yield
- -24.23%
Fundamentals
- Revenue
- $2.67B
- Net income
- -$1.05B
- EPS, diluted
- -$15.41
- Free cash flow
- -$211.20M
- Book value per share
- $25.99
- Diluted shares
- 68M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
$2.67B-2.5% YoY
Gross profit
$1.19B-8.0% YoY
Operating income
-$824.70M
Net income
-$1.05B
EPS, diluted
-$15.41
Free cash flow
-$211.20M-1724.6% YoY
Reported periodTrailing twelve months